Boehringer Ingelheim and Eli Lilly have commenced first ever trial to evaluate Jardiance (empagliflozin) in people hospitalised for acute heart failure who have been stabilised.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,